797 related articles for article (PubMed ID: 34220791)
1. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
2. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
3. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas.
Deng X; Lin D; Zhang X; Shen X; Yang Z; Yang L; Lu X; Yu L; Zhang N; Lin J
J Cell Physiol; 2020 Oct; 235(10):7321-7331. PubMed ID: 32162312
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Gene Expression Signature in Patients With Distinct Glioma Grades.
Ait Ssi S; Chraa D; El Azhary K; Sahraoui S; Olive D; Badou A
Front Immunol; 2021; 12():685213. PubMed ID: 34539626
[TBL] [Abstract][Full Text] [Related]
5.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
6. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
7. A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy.
Huang R; Lu X; Sun X; Wu H
Int J Immunopathol Pharmacol; 2024; 38():3946320241249395. PubMed ID: 38687369
[No Abstract] [Full Text] [Related]
8. Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma.
Chen Q; Han B; Meng X; Duan C; Yang C; Wu Z; Magafurov D; Zhao S; Safin S; Jiang C; Cai J
Int J Cancer; 2019 Jul; 145(2):517-530. PubMed ID: 30613962
[TBL] [Abstract][Full Text] [Related]
9. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
10. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.
Chai R; Zhang K; Wang K; Li G; Huang R; Zhao Z; Liu Y; Chen J
J Cancer Res Clin Oncol; 2018 Mar; 144(3):439-447. PubMed ID: 29299749
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
12. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
13. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment.
Jia D; Li S; Li D; Xue H; Yang D; Liu Y
Aging (Albany NY); 2018 Apr; 10(4):592-605. PubMed ID: 29676997
[TBL] [Abstract][Full Text] [Related]
14. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
15. Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas.
Bockmayr M; Klauschen F; Maire CL; Rutkowski S; Westphal M; Lamszus K; Schüller U; Mohme M
Cancer Immunol Res; 2019 Sep; 7(9):1401-1411. PubMed ID: 31266783
[TBL] [Abstract][Full Text] [Related]
16. A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma.
Sun Y; Sedgwick AJ; Palarasah Y; Mangiola S; Barrow AD
Front Immunol; 2021; 12():668391. PubMed ID: 34539622
[TBL] [Abstract][Full Text] [Related]
17. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
[TBL] [Abstract][Full Text] [Related]
18. Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma.
Haddad AF; Chen JS; Oh T; Pereira MP; Joshi RS; Aghi MK
Sci Rep; 2020 Oct; 10(1):17580. PubMed ID: 33067480
[TBL] [Abstract][Full Text] [Related]
19. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
20. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
